Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits

NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announced the publication of a paper in the journal Diabetes that serves as a roadmap for beta cell replacement therapies that can cure type 1 diabetes. The paper, "Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes" , was authored by a team of Breakthrough T1D leaders and staff, including Sanjoy Dutta , Ph.D., Chief Scientific Officer, Esther Latres, Ph.D., Vice President of Research, and Marjana Marinac , Pharm.D., Associate Vice Preside

See Full Page